Taizhou Mabtech Pharmaceutical Co.,ltd

This phase 3 trial tested whether a new biologic called CMAB015 works as well as secukinumab (Cosentyx) for moderate-to-severe plaque psoriasis. 336 adults received either drug for up to 48 weeks. The main goal was to see if at least 75% of skin symptoms improved by week 12. The …

This early-stage trial tested a new version of the allergy drug omalizumab (called CMAB007) against the original drug (Xolair) in 114 healthy Chinese men. The goal was to see how the body processes each drug, check for side effects, and compare immune responses. No treatment was …